The Promise and the Complexity- of Targeted Therapy
Targeted therapies represent one of the greatest advances in modern oncology, offering the potential to attack cancer with precision, minimise side effects, and overcome drug resistance that conventional chemotherapy cannot address.
But realising that potential depends on one critical prerequisite: understanding which cellular pathways are driving a patient’s cancer, and how those pathways interact with each other.
This study investigates exactly that: mapping the landscape of co-occurring prognostic cellular pathways across multiple cancer types to identify how cell proliferation alterations interact with other pathway abnormalities, and what that means for targeted therapy selection.
Our Study: 82 Pan-Cancer Patients Across 12 Tumour Types
In a retrospective analysis of 82 pan-cancer patients spanning 12 tumour types, including breast, colorectal, endometrial, gall bladder, gastric, head and neck, lung, melanoma, ovarian, pancreatic, prostate, and urothelial cancers; comprehensive genomic profiling was performed using our OncoIndx NGS assay to map the distribution and co-occurrence of key cellular pathways.
The pathways interrogated included cell proliferation, cell progression, double-strand DNA (dsDNA) repair, mismatch repair (MMR), tumour suppression, and cell signalling; providing a comprehensive, multi-pathway view of each patient’s tumour biology.
What the Genomic Landscape Revealed
Across the full cohort, 99 genomic alterations were detected and mapped to their respective cellular pathways:
- Cell proliferation pathway alterations were the most frequent; accounting for 43 mutations in 34.14% of patients; establishing this pathway as the dominant driver of oncogenic activity across the pan-cancer cohort
- Tumour suppressor gene alterations were equally prevalent, identified in 34.14% of patients with 31 alterations, highlighting the dual burden of proliferative activation and suppressive loss in many tumours
- MMR and cell signalling pathways accounted for a smaller proportion of alterations (2 and 1 respectively), reflecting their more selective prevalence across specific tumour types
Critically, cell proliferation pathway alterations were found to co-occur with multiple other pathways in a significant proportion of patients:
- Co-occurring tumour suppression alterations: n=13/28
- Co-occurring dsDNA repair alterations: n=3/28
- Co-occurring cell progression alterations: n=2/28
- Co-occurring MMR alterations: n=2/28
Two particularly instructive clinical cases emerged from this co-occurrence analysis.
One patient, who had recently undergone surgery with no evidence of recurrence or residual disease, and another who had been started on oral capecitabine chemotherapy; both showed co-occurring tumour suppression pathway alterations alongside cell proliferation mutations. This pattern of convergent pathway disruption warrants close clinical attention as a potential marker of therapeutic vulnerability.
Why This Matters
The co-occurrence of cell proliferation pathway alterations with tumour suppression, dsDNA repair, and MMR pathway abnormalities is not merely a genomic curiosity, it is a clinically significant finding that opens the door to multiple lines of targeted treatment that would not be apparent from single-pathway analysis alone.
For oncologists, this means that comprehensive pathway mapping rather than mutation-by-mutation analysis, may be the key to unlocking combination therapy strategies, identifying resistance mechanisms before they emerge, and maximising the precision of treatment selection across diverse cancer types.
This is exactly the depth of genomic insight our OncoIndx platform is designed to deliver.
Published at the ASCO Annual Meeting 2025 | DOI: 10.1200/JCO.2025.43.16_suppl.e15092
Presented by Sourav Kumar Mishra, MD, DM, MBBS | All India Institute of Medical Sciences, Bhubaneswar | Publication Only: Developmental Therapeutics:- Molecularly Targeted Agents and Tumor Biology Read Abstract